RoverMed has developed targeted, twenty nanometer nanocapsule technology capable of reaching the most challenging disease sites and delivering cargo – intact – into the nucleus of target cells, regardless of where these cells are located in the body.
RoverMed’s nanocapsule technology has been proven, through years of intensive research and development, by Minnesota-based GeneSegues Therapeutics. A precision target drug delivery platform has been developed initially for solid tumor cancers of the head and neck, prostate, and colon. RoverMed is now applying this technology toward a broader spectrum of treatment applications, in partnership with larger drug developers, in order to expand the acceptance, use and impact on a host of new, exciting applications.
RoverMed technology opportunities are being advanced through engagement with pharmaceutical and biotech companies, resulting in immediate revenue, lower costs and dramatically lower financial risk. RoverMed enables the success of pharmaceutical companies by incorporating their drugs in our delivery vehicle, which is readily modified – and customized – for different cell targets as needed. The goal: to help our pharmaceutical partners get their life-changing and live-saving drugs to exactly the right place in the body as efficiently as possible.